A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study. Issue 9 (March 2019)

• Record Type: Journal Article
• Authors: Cummings, Fraser; Gaya, Daniel R.; Levison, Scott; Subramanian, Sreedhar; Owen, Glynn; Rathmell, Anna; Glen, Fiona; Demuth, Dirk; Meadowcroft, Simon; Irving, Peter M.
• Other Names: Augustin. Goran section editor.
• Is Part Of: Medicine. Volume 98:Issue 9(2019)
• Publication Date: 2019-03
• Subjects: Crohn's disease -- inflammatory bowel disease -- tolerability -- treatment effectiveness -- treatment outcome -- treatment persistence -- ulcerative colitis -- vedolizumab; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000014681
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Results from clinical trials show that vedolizumab is an efficacious treatment for inflammatory bowel disease, namely Crohn's disease (CD) and ulcerative colitis (UC). However, there is limited evidence from real-world clinical practice, especially on early clinical experiences in the UK. To describe real-world early experiences of vedolizumab to treat CD and UC in the UK. A retrospective, chart review study of patients with CD or UC treated with vedolizumab across 5 UK hospitals. All eligible adults (≥18 years at initiation) with a diagnosis of CD and ≥14 weeks of data or UC and ≥10 weeks of data available following vedolizumab initiation were included. Data were analyzed for 112 patients (CD: 66; UC: 46). Patients with CD had a median of 7.4 (interquartile range 5.7–9.4) months follow-up and patients with UC had a median of 7.4 (5.6–10.2) months follow-up post-vedolizumab initiation. Most patients, 80% (53/66) with CD and 89% (41/46) with UC, remained on vedolizumab treatment at the time of data collection. No new safety signals were identified during the study. These results add to the body of evidence supporting vedolizumab as an effective and well-tolerated treatment for CD and UC in real-world clinical practice. Abstract : Supplemental Digital Content is available in the text